IMRX

+ Watchlist + Portfolio

Immuneering Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.33
52-Week Range: $3.70 – $10.08
Market Cap: $339.66M
P/E (TTM): —
EPS (TTM): -0.93
Dividend Yield: —

Advanced Metrics

Price/Book: 1.78
PEG Ratio: —
Return on Equity: -52.15%
Return on Assets: -32.77%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 19.47
Debt/Equity: 0.02
Total Debt: $3.63M
Free Cash Flow: $-39.35M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $198.57M

IMRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$316.95K	$0.00	$0.00	$0.00
Cost of Revenue	$158.12K	$0.00	—	—
Gross Profit	$158.83K	$0.00	—	—
Research & Development	$36.27M	$41.62M	$47.96M	$42.05M
Selling, General & Admin	$15.61M	$16.76M	$16.08M	$17.30M
Operating Expenses	$51.90M	$58.41M	$64.07M	$59.38M
Operating Income	-$51.75M	-$58.41M	-$64.07M	-$59.38M
EBITDA	-$51.47M	-$58.06M	-$63.69M	-$59.02M
Pretax Income	-$50.51M	-$53.47M	-$61.04M	-$56.02M
Income Tax	$0.00	—	—	—
Net Income	-$50.51M	-$53.47M	-$61.04M	-$56.02M
Diluted EPS	-1.91	-1.88	-2.04	-1.27
Diluted Shares	26.39M	28.42M	29.98M	44.01M

IMRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$72.64M	$59.41M	$36.14M	$128.65M
Receivables	$12.42K	$0.00	—	—
Current Assets	$108.75M	$89.08M	$39.59M	$176.25M
Total Assets	$122.37M	$102.58M	$52.71M	$231.99M
Current Liabilities	$8.05M	$7.85M	$7.50M	$10.07M
Total Debt	$4.84M	$4.46M	$4.16M	$3.82M
Total Liabilities	$12.52M	$12.01M	$11.33M	$13.50M
Retained Earnings	-$109.79M	-$163.26M	-$224.30M	-$280.32M
Shareholders' Equity	$109.85M	$90.58M	$41.39M	$218.48M
Working Capital	$100.69M	$81.24M	$32.08M	$166.17M

IMRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$44.10M	-$48.97M	-$55.00M	-$45.34M
Capital Expenditure	-$742.48K	-$342.75K	-$84.88K	-$142.23K
Free Cash Flow	-$44.84M	-$49.31M	-$55.08M	-$45.49M
Depreciation & Amortisation	$277.25K	$352.08K	$385.07K	$353.78K
Stock-Based Compensation	$4.06M	$5.73M	$6.50M	$6.31M
Investing Cash Flow	$41.83M	$7.30M	$26.43M	-$88.74M
Financing Cash Flow	$19.00K	$28.44M	$5.30M	$226.58M
Net Change in Cash	-$2.25M	-$13.23M	-$23.26M	$92.50M

IMRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$11.47M	$10.45M	$10.87M	$9.25M	$10.65M
Selling, General & Admin	$4.01M	$4.30M	$4.50M	$4.49M	$4.68M
Operating Expenses	$15.49M	$14.76M	$15.38M	$13.75M	$15.33M
Operating Income	-$15.49M	-$14.76M	-$15.38M	-$13.75M	-$15.33M
EBITDA	-$15.39M	-$14.67M	-$15.29M	-$13.67M	-$15.25M
Pretax Income	-$15.05M	-$14.43M	-$14.96M	-$11.58M	-$13.46M
Net Income	-$15.05M	-$14.43M	-$14.96M	-$11.58M	-$13.46M
Diluted EPS	-0.42	-0.40	-0.38	-0.18	-0.21
Diluted Shares	35.53M	35.99M	39.67M	64.59M	64.66M

IMRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$35.87M	$26.36M	$227.56M	$128.65M	$47.32M
Current Assets	$38.21M	$27.73M	$229.10M	$176.25M	$161.41M
Total Assets	$50.68M	$40.06M	$241.06M	$231.99M	$214.81M
Current Liabilities	$5.11M	$7.49M	$9.55M	$10.07M	$4.97M
Total Debt	$4.08M	$4.00M	$3.92M	$3.82M	$3.73M
Total Liabilities	$8.84M	$11.12M	$13.08M	$13.50M	$8.29M
Retained Earnings	-$239.34M	-$253.78M	-$268.74M	-$280.32M	-$293.78M
Shareholders' Equity	$41.84M	$28.94M	$227.98M	$218.48M	$206.52M
Working Capital	$33.10M	$20.24M	$219.56M	$166.17M	$156.43M

IMRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$14.08M	-$9.45M	-$11.98M	-$9.84M	-$18.43M
Capital Expenditure	-$8.95K	-$2.12K	-$7.25K	-$123.91K	-$79.93K
Free Cash Flow	-$14.09M	-$9.45M	-$11.98M	-$9.96M	-$18.51M
Depreciation & Amortisation	$92.58K	$91.84K	$86.16K	$83.21K	$88.72K
Stock-Based Compensation	$1.69M	$1.52M	$1.46M	$1.64M	$1.64M
Investing Cash Flow	-$8.95K	-$2.12K	-$7.25K	-$88.72M	-$63.07M
Financing Cash Flow	$13.81M	-$61.96K	$213.19M	-$357.52K	$180.76K
Net Change in Cash	-$279.02K	-$9.51M	$201.21M	-$98.92M	-$81.32M

Market Snapshot

About

Immuneering Corp. is a clinical-stage oncology company utilizing its computational Disease Cancelling Technology platform to develop targeted therapies. The company's platform analyzes disease-related gene expression patterns to identify optimal drug targets and predict clinical efficacy. Immuneering's pipeline includes small molecule inhibitors designed to treat cancers driven by specific oncogenic pathways, including RAS pathway mutations. The company combines computational biology, drug discovery, and clinical development to accelerate the creation of precision oncology medicines. Immuneering's data-driven approach aims to improve success rates in cancer drug development.